The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

Rheumatology

Volumn 34, Issue 4, 1995, Pages 334-342

  Rankin, E C C ^a   Choy, E H S ^b   Kassimos, D ^b   Kingsley, G H ^c   Sopwtth, A M ^d   Isenberg, D A ^a   Panayi, G S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^d UCB PHARMA   (Belgium)

Author keywords

Monoclonal antibody; Rheumatoid arthritis; Therapeutics; Tumour necrosis factor

Indexed keywords

C REACTIVE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERANCE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOPATHOGENESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYMPTOM;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; PAIN; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029044028     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/34.4.334     Document Type: Article

References (20)

1. Silman AJ. Epidemiology and the rheumatic diseases. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology. Oxford: Oxford University Press, 1993:499-513.
2. Spector TD, Scott DL. What happens to patients with rheumatoid arthritis? The long-term outcome of treatment. Clinical Rheumatol 1988;7:315-30.
3. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
4. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
5. Week J, Palombella VJ, Henriksen-DeStefano D et al. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 1986;163:632-43.
6. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
7. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;318:516-8.
8. Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993;36:1681-90.
9. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor « (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
10. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Scott DL, van Riel PL, van der Heijde D, Benke AS. Assessing disease activity in rheumatoid arthritis. Monograph on behalf of the EULAR standing committee for international clinical studies, 1994.
12. Stephens S, Athwal D, Chaplin L et al. Pharmacokinetics of CDP571, an anti-TNFoe engineered human antibody, in the cynomolgus monkey and man. Circulatory Shock 1993;suppl. 1:60.
13. Beutler B, Greenwald D, Huhnes JD et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4.
14. Roubenoff R, Roubenoff RA, Cannon JG et al. Rheumatoid cachexia: cytolrine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994;93:2379-86.
15. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH. The pivotal role of tumour necrosis factor a in the development of inflammatory hyperalgesia. Br J Pharmacol 1992;107:660-4.
16. Choy EHS, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaerie anti-CD4 monoclonal antibody. Seoul J Immunol 1992:36:291-8.
17. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993:20:259-62.
18. Kavanaugh AF, Nichols LA, Lipsky PE. Treatment of refractory rheumatoid arthritis with an anti-CD54 (intercellular adhesion molecule-1, ICAM-1) monoclonal antibody. Arthritis Rheum 1992;35(suppl. 9):43.
19. Van der Heijde DM FM, van Riel PLCM, van Leeuwen MA, van’t Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
20. Castell JV, Gomez-Lechon MJ, David M et al. Inter-leukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989:242:237-9.